P011 - SectionFront Standard Page
Allergy immunotherapy
The World Health Organisation (WHO) recognizes allergy immunotherapy (vaccination) as the only approach that targets the cause of allergy and alters the natural course of the disease.

The benefits that can be gained from allergy immunotherapy are reflected in the current ARIA (Allergic Rhinitis and its Impact on Asthma) treatment guidelines, which recommend early treatment in the disease process in order to prevent further development of allergic rhinitis and/or asthma.
Visit the ARIA website


Burden of allergic disease 


Allergy is a widespread disease, which is becoming increasingly common worldwide and has a tendency to aggravate with time. Currently, more than 20% of the population suffer from respiratory allergies.

For most allergy sufferers, their allergy leads to a significantly reduced quality of life, affecting both work and leisure time. Allergic patients can relieve symptoms by self-imposing restrictions on activities to avoid allergen exposure. Self-imposed restrictions may have psychological and social consequences. Allergic disease has significant socio-economic impact on the patient, the patient’s family and the society as a whole. According to a European survey of diagnosed allergy sufferers, around 80% of the respondents find that their disease considerably affects their daily activities.

The growing prevalence of allergy also has major economic consequences for society through reduced working capacity and more sick leave, placing a greater burden on healthcare resources and increasing medication costs.

Effects of allergic disease